在一个30例患者的小规模研究中，pidilizumab加利妥昔单抗在复发的滤泡性淋巴瘤中取得了66%的总有效率，其中大部分是完全缓解。
In a small 30-patient study, pidilizumabplus rituximab demonstrated an ORR of 66% in relapsed follicular lymphoma, which primarily consisted of complete responses.
作者描述88例CD5+的滤泡性淋巴瘤临床病理学特征（男性53例，女性35例；
We describe the clinicopathologic features of 88 cases of CD5+ follicular lymphoma (53 men, 35 women;
作者描述88例CD5+的滤泡性淋巴瘤临床病理学特征（男性53例，女性35例；
We describe the clinicopathologic features of 88 cases of CD5+ follicular lymphoma (53 men, 35 women;
应用推荐